ASH Annual Meeting & Exposition: Lymphoma | Conference

Michael R. Bishop, MD, Discusses Impact of Tisa-Cel on B-Cell NHL From BELINDA Trial
February 09, 2022

Michael R. Bishop, MD, discussed how he thinks the results from phase 3 BELINDA study may impact the treatment landscape in B-cell lymphomas moving forward.

Michael R. Bishop, MD, on Patient Selection in BELINDA Trial of Tisa-Cel in R/R B-Cell Non-Hodgkin Lymphoma
February 02, 2022

Michael R. Bishop, MD, highlighted the population of patients with relapsed/refractory B-cell non-Hodgkin lymphoma who were enrolled on the phase 3 BELINDA study and treated with tisagenlecleucel.

Amitkumar Mehta, MD, Discusses the Role of Parsaclisib in Relapsed/Refractory MCL
January 25, 2022

Amitkumar Mehta, MD, discusses the role of parsaclisib and how it fits into the treatment landscape of relapsed/refractory mantle cell lymphoma.

Sattva S. Neelapu, MD, Discusses Further ZUMA-5 Follow-up on Axi-Cel for R/R iNHL
December 16, 2021

Sattva S. Neelapu, MD, spoke about continuing to look at results from the ZUMA-5 trial to determine if axicabtagene ciloleucel can cure patients with relapsed or refractory indolent non-Hodgkin lymphoma

Treatment With Tafasitamab, Lenalidomide, and R-CHOP Yields Promising Activity in Untreated DLBCL
December 14, 2021

Patients with previously untreated diffuse large B-cell lymphoma experienced promising responses after being treated with tafasitamab-cxix and lenalidomide plus rituximab, cyclophosphamide, doxorubicin, vincristin, and prednisone.

First-Line Axi-Cel Yields Rapid Response in Large B-Cell Lymphoma
December 14, 2021

Patients with high-risk large B-cell lymphoma saw durable responses when treated with axicabtagene ciloleucel.

Progression-Free Survival Boost Noted With Polatuzumab Vedotin Plus R-CHP for Previously Untreated DLBCL
December 14, 2021

A 27% reduction in the risk of progression or death was noted when polatuzumab vedotin was added on R-CHP vs R-CHOP for patients with intermediate- or high-risk diffuse large B-cell lymphoma who received treatment in the first line.

Duvelisib Plus Romidepsin Yields High Results in Relapsed/Refractory Peripheral T-Cell Lymphoma
December 13, 2021

A positive overall response rate was achieved when patients with relapsed/refractory peripheral T-cell lymphoma were treated with duvelisib plus romidespin.

Axi-Cel Yields Efficacy in Previously Excluded LBCL Real-World Populations
December 13, 2021

Patients with large B-cell lymphoma who were previously excluded from investigations experienced increased efficacy with the use of axicabtagene ciloleucel.

Glofitamab Alone or Combined With Obinutuzumab Produced Strong Responses in Relapsed/Refractory Follicular Lymphoma
December 13, 2021

Glofitamab monotherapy or in combination with obinutuzumab led to strong response rates for patients with multiple relapsed or refractory follicular lymphoma.